Tag

Merck

All articles tagged with #merck

business4 days ago•3 min saved

Merck Restructures to Stand Up a Dedicated Oncology Unit Ahead of Keytruda's Patent Cliff

Merck is splitting its human health business into two divisions—a dedicated oncology unit to oversee cancer therapies (including Keytruda) and a separate specialty pharma and infectious diseases unit for non-cancer products and vaccines—part of a strategy to sharpen growth after Keytruda's looming patent cliff. The company cites expectations of continued leadership in oncology and potential multi-brand growth, highlighting leadership changes: Jannie Oosthuizen will run the oncology and international unit, while Brian Foard heads the new specialty/pharma/infectious diseases unit, with Chirfi Guindo in a policy/communications role. Merck aims to sustain long-term oncology leadership and push growth through its pipeline, with executives signaling potential of more than $70B in annual revenue mid-decade.

via Fierce Pharma|

#business #corporate-reorganization #keytruda

business4 days ago•18 min saved

Merck Restructures Human Health to Accelerate Launches Across a Diversified Portfolio

Merck is reorganizing its Human Health unit into two business units—Oncology and Specialty, Pharma & Infectious Diseases—to sharpen commercial execution for a broader portfolio. New leaders Jannie Oosthuizen (Oncology) and Brian Foard (Specialty, Pharma & Infectious Diseases) will report to CEO Robert Davis, while Chirfi Guindo leads Strategic Access, Policy & Communications. The move aims to better advance Merck’s widening pipeline, with about 80 Phase 3 trials and more than 20 growth drivers anticipated in the coming years.

via Merck.com|

#business #human-health #infectious-diseases

business4 days ago•1 min saved

Merck reshapes structure to create dedicated cancer unit led by Keytruda

Merck will split its human-health business into two units: a cancer-focused division led by Keytruda and a separate non-oncology medicines arm, as the company diversifies ahead of Keytruda’s looming loss of exclusivity. Keytruda remains the world’s top-selling drug, with more than $30 billion in revenue in 2025, accounting for about half of Merck’s total revenue. Shares rose about 1.4% in premarket trading. Merck has expanded its pipeline and made major acquisitions to bolster growth, and appointed Jannie Oosthuizen to lead the new cancer unit.

via CNBC|

#business #cancer #corporate-split

health23 days ago•14 min saved

Merck’s experimental cholesterol-pill shows strong LDL reduction in a large trial

Merck reported that its experimental pill, elicitide, delivered a sharp reduction in cholesterol in a large clinical trial, signaling potential for a new therapy to lower cholesterol. Details on exact numbers and safety data were not provided in the summary, with further results anticipated.

via AP News|

#cardiovascular-health #cholesterol #clinical-trial

markets24 days ago

Premarket Movers Spotlight: Palantir, Merck, Pfizer Lead Early Trading

Palantir (PLTR), Merck (MRK), and Pfizer (PFE) were among the biggest movers in premarket trading, with Market Insider noting several other names as the session began.

via CNBC|

#markets #merck #palantir

business1 month ago•3 min saved

Merck walks away from Revolution Medicines deal over valuation gap

Merck ended discussions to acquire Revolution Medicines due to a valuation disagreement, effectively halting the deal. Investor interest in Revolution’s cancer-drug pipeline remains buoyant ahead of several key clinical trial results later this year, with Mizuho Securities estimating Revolution’s pancreatic cancer drug could reach about $10 billion in annual global sales by 2035 if the trials prove successful and safe.

via Seeking Alpha|

#acquisition #biotech #business

business1 month ago•0 min saved

Merck in Negotiations to Acquire Revolution Medicines for Up to $32 Billion

Merck is in negotiations to acquire biotech firm Revolution Medicines, with the deal not yet finalized and other bidders potentially involved, causing Revolution's shares to rise.

via Yahoo Finance|

#acquisition #biotech #business

business1 month ago•1 min saved

Merck in Talks to Acquire Revolution Medicines in Up to $32 Billion Deal

Merck is in negotiations to acquire Revolution Medicines, a cancer drug developer, for up to $32 billion, signaling a significant move in the biotech and pharmaceutical industry.

via Financial Times|

#acquisition #biotech #business

business2 months ago•4 min saved

Top 3 Discounted Drug Stocks to Watch

The article discusses the recent developments in the GLP-1 drug market, highlighting Novo Nordisk's new pill and the potential of out-of-favor drug makers like Bristol Myers Squibb, Merck, and Pfizer as long-term investment opportunities due to their efforts to innovate and survive patent cliffs. Despite current setbacks, these companies are positioned for future growth, making them attractive for contrarian investors.

via The Motley Fool|

#business #glp-1-drugs #merck

business2 months ago•0 min saved

Trump Secures Drug Price Reductions with Nine Major Pharma Companies

Several major pharmaceutical companies, including Merck, struck drug-pricing agreements with the Trump administration, joining other industry leaders in negotiations over drug prices.

via Investor's Business Daily|

#business #drug-agreements #drug-pricing

business2 months ago•5 min saved

Major Pharma Companies and Trump Administration Agree to Lower Drug Prices

Merck has reached an agreement with the U.S. government to improve access to medicines and lower costs for Americans, including offering key drugs at significantly reduced prices through a direct-to-patient program and investing over $70 billion in U.S. manufacturing and R&D to bolster domestic innovation and job creation.

via Merck.com|

#affordable-medicines #business #drug-pricing

health3 months ago•1 min saved

Merck's PCSK9 Pill Shows Promise in Lowering LDL Cholesterol

Merck's oral PCSK9 inhibitor, Enlicitide, significantly reduces LDL cholesterol by up to 60% in high-risk patients already on statins, matching the efficacy of injectable treatments, according to a late-stage clinical trial.

via statnews.com|

#cardiovascular #cholesterol #clinical-trial

healthcare3 months ago•9 min saved

Merck's New Oral PCSK9 Inhibitor Shows Promise in Lowering Cholesterol

Merck announced promising Phase 3 trial results showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduces LDL cholesterol by over 55% with a safety profile similar to placebo, potentially offering a new oral treatment for cardiovascular disease prevention.

via Merck.com|

#cardiovascular-health #enlicitide #healthcare

health3 months ago•2 min saved

Merck's PCSK9 Pill Shows Promise in Lowering Cholesterol to Injectable Levels

Merck has developed a new pill called enlicitide that significantly reduces LDL cholesterol levels by blocking the PCSK9 protein, showing promising results in clinical trials with a 20% reduction in heart attack and stroke rates among high-risk patients, and offering a potentially more affordable alternative to existing injectable treatments.

via The New York Times|

#cholesterol #enlicitide #health

business4 months ago•3 min saved

Merck's Q3 2025 Profit Rises Amid Keytruda Strength and Sales Fluctuations

Merck's stock declined after its key products, Keytruda and Winrevair, fell short of sales estimates, despite overall revenue beating expectations. The company is preparing for biosimilar competition for Keytruda starting in 2028 and has made significant acquisitions to offset potential revenue declines. Merck has also updated its full-year outlook, expecting slight increases in sales and earnings for 2025.

via Barron's|